Aug. 13 at 12:19 PM
$MEDXF
🚨
GRAFAPEX launch generated
$3.0M in first full quarter revenue
Strong market adoption with 36 transplant centers (24% of US procedures) already ordering
Achieved positive net income of
$0.5M and Adjusted EBITDA of
$3.4M
Significant debt reduction of
$15.5M, lowering total debt to
$22.0M
Obtained NTAP approval for GRAFAPEX with maximum reimbursement of
$21,411 per eligible case
Improved gross margin to 56.0% from 54.4% year-over-year
Net revenue decreased 9.9% year-over-year to
$24.6M
Adjusted EBITDA declined 44.3% year-over-year to
$3.4M
Operating income fell 77.5% to
$0.9M compared to prior year
Available liquidity decreased to
$9.3M from
$24.0M in March 2025
Rupall facing significant revenue erosion due to generic competition
New 15% tariff on EU pharmaceutical imports affecting GRAFAPEX and Rasuvo
